We herein report a case of Guillain-BarrĂ© syndrome (GBS) after SARS-CoV-2 an infection. The affected person was an in depth contact with a SARS-CoV-2 affected person. Initially, she didn’t have any signs and quarantined at a resort. Dysgeusia and olfactory abnormality appeared at day 6 after testing constructive for an infection and disappeared by day 9.
Subsequently, the affected person developed numbness of the legs and arms, issue strolling, and dyspnea and was referred to our hospital. Her scientific examination confirmed generalized weak spot and hyporeflexia. A cerebrospinal fluid evaluation confirmed albuminocytological dissociation. Her nerve conduction research had been in keeping with demyelinating polyneuropathy. Intravenous immunoglobulin was administered primarily based on a analysis of GBS.
Telaprevir is a possible drug for repurposing towards SARS-CoV-2: computational and in vitro research
Drug repurposing is a vital method to the project of already authorised medication for brand spanking new indications. This system bypasses some steps within the conventional drug approval system, which saves time and lives within the case of pandemics. Direct appearing antivirals (DAAs) have repeatedly repurposed from treating one virus to a different.
On this research, 16 FDA-approved hepatitis C virus (HCV) DAA medication had been studied to discover their actions towards extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) human and viral targets. Among the many 16 HCV DAA medication, telaprevir has proven one of the best in silico proof to work on each oblique human targets (cathepsin L [CTSL] and human angiotensin-converting enzyme 2 [hACE2] receptor) and direct viral targets (fundamental protease [Mpro]).
Furthermore, the docked poses of telaprevir inside each hACE2 and Mprofessional had been subjected to further molecular dynamics simulations monitored by calculating the binding free vitality utilizing MM-GBSA. In vitro evaluation of telaprevir confirmed inhibition of SARS-CoV-2 replication in cell tradition (IC50 = 11.552 μM, CC50 = 60.865 μM, and selectivity index = 5.27). Accordingly, primarily based on the in silico research and supported by the offered in vitro evaluation, we recommend that telaprevir could also be thought-about for therapeutic growth towards SARS-CoV-2.
Focusing on Intra-Viral Conserved Nucleocapsid (N) Proteins as Novel Vaccines towards SARS-CoVs
Extreme Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has brought on the worldwide pandemic of the Coronavirus illness in late 2019 (COVID-19). Vaccine growth efforts have predominantly been geared toward ‘Further-viral’ Spike (S) protein as vaccine autos however there are considerations relating to ‘viral immune escape’ since a number of mutations could allow the mutated virus strains to flee from immunity towards S protein. The ‘Intra-viral’ Nucleocapsid (N-protein) is comparatively conserved amongst mutant strains of coronaviruses throughout unfold and evolution.
Herein, we reveal novel vaccine candidates towards SARS-CoV-2 through the use of the entire conserved N-protein or its fragment/peptides. Utilizing ELISA assay, we confirmed that prime titers of particular anti-N antibodies (IgG, IgG1, IgG2a, IgM) had been maintained for a fairly lengthy length (> 5 months), suggesting that N-protein is a superb immunogen to stimulate host immune system and strong B cell activation.
We synthesized three peptides situated on the conserved areas of N-protein amongst CoVs. One peptide confirmed as a very good immunogen for vaccination as effectively. Cytokine arrays on post-vaccination mouse sera confirmed progressive upregulation of varied cytokines corresponding to IFN-γ and CCL5, suggesting that TH1 related responses are additionally stimulated.
Moreover, vaccinated mice exhibited an elevated reminiscence T cells inhabitants. Right here, we suggest an unconventional vaccine technique concentrating on the conserved N-protein in its place vaccine goal for coronaviruses. Furthermore, we generated a mouse monoclonal antibody particularly towards an epitope shared between SARS-CoV and SARS-CoV-2, and we’re presently creating the First-in-Class humanized anti-N-protein antibody to doubtlessly deal with sufferers contaminated by numerous CoVs sooner or later.
|
MULTIPLEX KIT PCR MASTITIS PCR kit |
|
PCR-MPX218-48D |
Bioingentech |
|
MULTIPLEX KIT PCR MASTITIS PCR kit |
|
PCR-MPX218-96D |
Bioingentech |
|
MULTIPLEX KIT PCR Babesia & Theileria PCR kit |
|
PCR-MPX401-48D |
Bioingentech |
|
MULTIPLEX KIT PCR Babesia & Theileria PCR kit |
|
PCR-MPX401-96D |
Bioingentech |
|
Taq PCR Kit |
|
40-5211-01 |
Gene Link |
The SARS-CoV-2 spike protein is weak to average electrical fields
A lot of the ongoing tasks aimed on the growth of particular therapies and vaccines towards COVID-19 use the SARS-CoV-2 spike (S) protein as the principle goal. The binding of the spike protein with the ACE2 receptor (ACE2) of the host cell constitutes the primary and key step for virus entry.
Throughout this course of, the receptor binding area (RBD) of the S protein performs a necessary function, because it incorporates the receptor binding motif (RBM), accountable for the docking to the receptor. Up to now, largely biochemical strategies are being examined with the intention to forestall binding of the virus to ACE2.
Right here we present, with the assistance of atomistic simulations, that exterior electrical fields of simply achievable and average strengths can dramatically destabilise the S protein, inducing long-lasting structural harm. One hanging field-induced conformational change happens on the degree of the popularity loop L3 of the RBD the place two parallel beta sheets, believed to be accountable for a excessive affinity to ACE2, bear a turn into an unstructured coil, which displays nearly no binding prospects to the ACE2 receptor.
We additionally present that these extreme structural modifications upon electric-field software additionally happen within the mutant RBDs akin to the variants of concern (VOC) B.1.1.7 (UK), B.1.351 (South Africa) and P.1 (Brazil). Remarkably, whereas the structural flexibility of S permits the virus to enhance its likelihood of getting into the cell, additionally it is the origin of the stunning vulnerability of S upon software of electrical fields of strengths a minimum of two orders of magnitude smaller than these required for damaging most proteins.
Our findings recommend the existence of a clear bodily technique to weaken the SARS-CoV-2 virus with out additional biochemical processing. Furthermore, the impact may very well be used for an infection prevention functions and likewise to develop applied sciences for in-vitro structural manipulation of S. For the reason that technique is basically unspecific, it may be appropriate for software to different mutations in S, to different proteins of SARS-CoV-2 and basically to membrane proteins of different virus sorts.
|
MELISA-TEK® Meat Species Ruminant Kit |
|
510311 |
ELISA Technologies |
|
MELISA-TEK® Meat Species Pork Kit |
|
510321 |
ELISA Technologies |
|
MELISA-TEK® High Sensitivity Extraction Kit |
|
510391 |
ELISA Technologies |
|
Meat Speciation : EZ Pangasiusâ„¢ |
|
510EZP |
ELISA Technologies |
|
Meat Speciation : EZ Porkâ„¢ |
|
530EZPK-10 |
ELISA Technologies |
Airborne SARS-CoV-2 surveillance in hospital surroundings utilizing high-flowrate air samplers and its comparability to floor sampling
Dependable strategies to detect the presence of SARS-CoV-2 at venues the place folks collect are important for epidemiological surveillance to information public coverage. Communal screening of air in a extremely crowded house has the potential to supply early warning on the presence and potential transmission of SARS-CoV-2 as recommended by research early within the epidemic.
As hospitals and public services apply various levels of restrictions and laws, you will need to present a number of methodological choices to allow environmental SARS-CoV-2 surveillance beneath completely different circumstances. This research assessed the feasibility of utilizing high-flowrate air samplers mixed with RNA extraction package designed for environmental pattern to carry out airborne SARS-CoV-2 surveillance in hospital setting, examined by RT-qPCR.
The success charge of the air samples in detecting SARS-CoV-2 was then in contrast with floor swab samples collected in the identical proximity. Moreover, constructive RT-qPCR samples underwent viral tradition to evaluate the viability of the sampled SARS-CoV-2.
The research was carried out in inpatient ward environments of a quaternary care college educating hospital in Singapore housing lively COVID-19 sufferers throughout the interval of February to Could 2020. Two sorts of wards had been examined, naturally ventilated open-cohort ward and mechanically ventilated isolation ward. Distances between the location of air sampling and the affected person cluster within the investigated wards had been additionally recorded.
No profitable detection of airborne SARS-CoV-2 was recorded when 50 L/min air samplers had been used. Upon growing the sampling flowrate to 150 L/min, our outcomes confirmed a excessive success charge in detecting the presence of SARS-CoV-2 from the air samples (72%) in comparison with the floor swab samples (9.6%). The constructive detection charge of the air samples together with the corresponding viral load may very well be related to the gap between sampling web site and affected person.
Rabbit IgG Anti SARS-CoV-2 Spike (S1) RBD Polyclonal Antibody |
|
PAB21476-500 |
The Native Antigen Company |
0.5 |
EUR 1270.82 |
|
Description: Rabbit polyclonal to SARS-CoV-2 receptor binding domain (RBD). |
SARS Spike Protein Polyclonal Antibody |
|
MBS191597-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191597-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191598-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191598-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191599-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191599-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191600-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191600-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191601-01mL |
MyBiosource |
0.1mL |
EUR 370 |
SARS Spike Protein Polyclonal Antibody |
|
MBS191601-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1650 |
SARS-CoV-2 Spike Glycoprotein Rabbit anti-Human Polyclonal Antibody |
|
MBS2403884-005mg |
MyBiosource |
0.05mg |
EUR 615 |
SARS-CoV-2 Spike Glycoprotein Rabbit anti-Human Polyclonal Antibody |
|
MBS2403884-5x005mg |
MyBiosource |
5x0.05mg |
EUR 2605 |
SARS-CoV-2 Spike Glycoprotein Rabbit anti-Human Polyclonal Antibody |
|
MBS2403885-005mg |
MyBiosource |
0.05mg |
EUR 595 |
SARS-CoV-2 Spike Glycoprotein Rabbit anti-Human Polyclonal Antibody |
|
MBS2403885-5x005mg |
MyBiosource |
5x0.05mg |
EUR 2500 |
SARS-CoV-2 Spike polyclonal antibody |
|
BS80243 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
SARS-CoV Spike RBD polyclonal antibody |
|
BS80270 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
Rabbit Anti-SARS-CoV-2 Spike Polyclonal antibody |
|
CABT-CS066 |
Creative Diagnostics |
50 µl |
EUR 756 |
|
Description: Rabbit |
SARS-CoV-2 Spike S1 polyclonal antibody |
|
BS80242 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
SARS-CoV-2 Spike S1 polyclonal antibody |
|
BS80269 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
SARS-CoV-2 Spike S2 polyclonal antibody |
|
BS77972 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
SARS-CoV-2 Spike RBD polyclonal antibody |
|
BS80241 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
SARS-CoV-2 Spike RBD Polyclonal Antibody |
|
EGVR1002 |
EnoGene |
2019-nCoV-rabbit-polyclonal-antibody |
EUR 276.5 |
|
Description: 2019-nCoV rabbit polyclonal antibody |
SARS-CoV-2 Spike RBD Polyclonal Antibody |
|
MBS8574970-01mg |
MyBiosource |
0.1mg |
EUR 475 |
SARS-CoV-2 Spike RBD Polyclonal Antibody |
|
MBS8574970-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1985 |
SARS-COV/SARS-COV-2 Spike RBD Polyclonal Antibody(2019-nCoV) |
|
MBS2563840-005mL |
MyBiosource |
0.05mL |
EUR 275 |
SARS-COV/SARS-COV-2 Spike RBD Polyclonal Antibody(2019-nCoV) |
|
MBS2563840-01mL |
MyBiosource |
0.1mL |
EUR 415 |
SARS-COV/SARS-COV-2 Spike RBD Polyclonal Antibody(2019-nCoV) |
|
MBS2563840-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1815 |
SARS-CoV-2 Spike S2 ECD polyclonal antibody |
|
BS77919 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
Anti-Spike (SARS-CoV) Rabbit Polyclonal Antibody |
|
MBS434242-01mg |
MyBiosource |
0.1mg |
EUR 345 |
Anti-Spike (SARS-CoV) Rabbit Polyclonal Antibody |
|
MBS434242-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1405 |
SARS-COV-2 Spike S2 Polyclonal Antibody(2019-nCoV) |
|
E-AB-V1010-100uL |
Elabscience Biotech |
100uL |
EUR 415 |
|
|
|
Description: Unconjugated |
SARS-COV-2 Spike S2 Polyclonal Antibody(2019-nCoV) |
|
E-AB-V1010-50uL |
Elabscience Biotech |
50uL |
EUR 250 |
|
|
|
Description: Unconjugated |
SARS-COV-2 Spike S2 Polyclonal Antibody(2019-nCoV) |
|
E-AB-V1010-each |
Elabscience Biotech |
each |
Ask for price |
|
|
|
Description: Unconjugated |
SARS-COV-2 Spike S2 Polyclonal Antibody (2019-nCoV) |
|
MBS2567078-005mL |
MyBiosource |
0.05mL |
EUR 275 |
SARS-COV-2 Spike S2 Polyclonal Antibody (2019-nCoV) |
|
MBS2567078-01mL |
MyBiosource |
0.1mL |
EUR 415 |
SARS-COV-2 Spike S2 Polyclonal Antibody (2019-nCoV) |
|
MBS2567078-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1815 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified |
|
IRBAHUCOV2ST1AP100UG |
Innovative research |
each |
EUR 640 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified |
|
MBS8421186-01mg |
MyBiosource |
0.1mg |
EUR 865 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified |
|
MBS8421186-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3715 |
SARS-COV-2 Spike RBD Polyclonal Antibody (2019-nCoV) |
|
E-AB-V1006-100uL |
Elabscience Biotech |
100uL |
EUR 415 |
|
|
|
Description: Unconjugated |
SARS-COV-2 Spike RBD Polyclonal Antibody (2019-nCoV) |
|
E-AB-V1006-50uL |
Elabscience Biotech |
50uL |
EUR 250 |
|
|
|
Description: Unconjugated |
SARS-COV-2 Spike RBD Polyclonal Antibody (2019-nCoV) |
|
E-AB-V1006-each |
Elabscience Biotech |
each |
Ask for price |
|
|
|
Description: Unconjugated |
SARS-CoV Spike Antibody, Rabbit MAb |
|
MBS8574841-01mg |
MyBiosource |
0.1mg |
EUR 675 |
SARS-CoV Spike Antibody, Rabbit MAb |
|
MBS8574841-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2995 |
Rabbit Anti Human SARS-CoV-2 Spike Protein 681P Polyclonal Affinity Purified |
|
IRBAHUST1681PAP100UG |
Innovative research |
each |
EUR 553 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein 681P Polyclonal Affinity Purified |
SARS-CoV-2 Spike Protein (S Protein) Polyclonal Antibody |
|
EGVR1001 |
EnoGene |
2019-nCoV-rabbit-polyclonal-antibody |
EUR 276.5 |
|
Description: 2019-nCoV rabbit polyclonal antibody |
SARS-CoV-2 Spike Protein (S Protein) Polyclonal Antibody |
|
MBS8574969-01mg |
MyBiosource |
0.1mg |
EUR 475 |
SARS-CoV-2 Spike Protein (S Protein) Polyclonal Antibody |
|
MBS8574969-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1985 |
SARS-COV-2 Spike RBD(Omicron) Protein polyclonal antibody |
|
BS80373 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
Rabbit Anti Human SARS-CoV-2 Spike Protein 156-157EF Polyclonal Affinity Purified |
|
IRBAHUST1156157EFAP100UG |
Innovative research |
each |
EUR 553 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein 156-157EF Polyclonal Affinity Purified |
SARS-CoV/SARS-CoV-2 Spike Antibody (HRP), Rabbit MAb |
|
MBS8119486-01mg |
MyBiosource |
0.1mg |
EUR 520 |
SARS-CoV/SARS-CoV-2 Spike Antibody (HRP), Rabbit MAb |
|
MBS8119486-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2185 |
SARS-CoV-2 Spike Antibody, Rabbit MAb |
|
MBS8119555-002mL |
MyBiosource |
0.02mL |
EUR 325 |
SARS-CoV-2 Spike Antibody, Rabbit MAb |
|
MBS8119555-01mL |
MyBiosource |
0.1mL |
EUR 580 |
SARS-CoV-2 Spike Antibody, Rabbit MAb |
|
MBS8119555-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2460 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified HRP Labeled |
|
IRBAHUCOV2ST1APHRP100UG |
Innovative research |
each |
EUR 617 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified HRP Labeled |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified HRP Labeled |
|
MBS8421189-01mg |
MyBiosource |
0.1mg |
EUR 840 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified HRP Labeled |
|
MBS8421189-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3590 |
SARS-CoV/SARS-CoV-2 Spike Antibody (Biotin), Rabbit MAb |
|
MBS8119485-01mg |
MyBiosource |
0.1mg |
EUR 520 |
SARS-CoV/SARS-CoV-2 Spike Antibody (Biotin), Rabbit MAb |
|
MBS8119485-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2185 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified FITC Labeled |
|
IRBAHUCOV2ST1APFITC100UG |
Innovative research |
each |
EUR 617 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified FITC Labeled |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified FITC Labeled |
|
MBS8421188-01mg |
MyBiosource |
0.1mg |
EUR 840 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified FITC Labeled |
|
MBS8421188-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3590 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified Biotin Labeled |
|
IRBAHUCOV2ST1APBL100UG |
Innovative research |
each |
EUR 617 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified Biotin Labeled |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified Biotin Labeled |
|
MBS8421187-01mg |
MyBiosource |
0.1mg |
EUR 840 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Polyclonal Affinity Purified Biotin Labeled |
|
MBS8421187-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3590 |
Anti-spike protein (SARS-CoV-2) rabbit polyclonal antibody |
|
MBS434317-01mg |
MyBiosource |
0.1mg |
EUR 385 |
Anti-spike protein (SARS-CoV-2) rabbit polyclonal antibody |
|
MBS434317-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1580 |
Rabbit Anti-HCoV OC43 Spike Polyclonal antibody |
|
CABT-CS063 |
Creative Diagnostics |
100 µg |
EUR 934.08 |
|
Description: Rabbit |
Rabbit Anti Human SARS-CoV-2 Spike Protein Gamma Variant P26S Polyclonal Affinity Purified |
|
IRBAHUST1GP26SAP100UG |
Innovative research |
each |
EUR 553 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein Gamma Variant P26S Polyclonal Affinity Purified |
SARS-Spike protein, Polyclonal Antibody (SARS-Spike Antibody) |
|
PT_72366 |
Novatein Biosciences, Inc. |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
Rabbit Anti Human SARS-CoV-2 Spike Protein Delta Variant L452R Polyclonal Affinity Purified |
|
IRBAHUST1DL452RAP100UG |
Innovative research |
each |
EUR 553 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein Delta Variant L452R Polyclonal Affinity Purified |
SARS-CoV-2 Spike Antibody (Biotin), Rabbit Mab |
|
MBS8124173-01mg |
MyBiosource |
0.1mg |
EUR 830 |
SARS-CoV-2 Spike Antibody (Biotin), Rabbit Mab |
|
MBS8124173-5x01mg |
MyBiosource |
5x0.1mg |
EUR 3595 |
SARS-CoV Spike Rabbit pAb |
|
A20605 |
Abclonal |
20μL |
EUR 88.56 |
SARS-CoV Spike Rabbit pAb |
|
E45R29003N |
EnoGene |
50 ul |
EUR 297.75 |
SARS-CoV Spike Rabbit pAb |
|
MBS9144354-002mL |
MyBiosource |
0.02mL |
EUR 200 |
SARS-CoV Spike Rabbit pAb |
|
MBS9144354-005mL |
MyBiosource |
0.05mL |
EUR 255 |
SARS-CoV Spike Rabbit pAb |
|
MBS9144354-01mL |
MyBiosource |
0.1mL |
EUR 345 |
SARS-CoV Spike Rabbit pAb |
|
MBS9144354-02mL |
MyBiosource |
0.2mL |
EUR 545 |
SARS-CoV Spike Rabbit pAb |
|
MBS9144354-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
Rabbit anti-HCoV spike glycoprotein polyclonal antibody |
|
CABT-RM317 |
Creative Diagnostics |
50 μl |
EUR 572.25 |
|
Description: Rabbit |
Rabbit Anti Human SARS-CoV-2 Spike Protein Delta Variant 156-157EF Polyclonal Affinity Purified |
|
IRBAHUST1D156157EFAP100UG |
Innovative research |
each |
EUR 553 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein Delta Variant 156-157EF Polyclonal Affinity Purified |
Anti-SARS-CoV-2 Spike RBD, HRPO (Polyclonal)(Rabbit IgG) |
|
MBS524576-01mg |
MyBiosource |
0.1mg |
EUR 410 |
Anti-SARS-CoV-2 Spike RBD, HRPO (Polyclonal)(Rabbit IgG) |
|
MBS524576-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1605 |
Rabbit Anti Human SARS-CoV-2 Spike Protein Alpha Mu Variant P681H Polyclonal Affinity Purified |
|
IRBAHUST1AMP681HAP100UG |
Innovative research |
each |
EUR 553 |
|
|
|
Description: Rabbit Anti Human SARS-CoV-2 Spike Protein Alpha Mu Variant P681H Polyclonal Affinity Purified |
Anti-SARS-CoV-2 Spike RBD, Biotin (Polyclonal)(Rabbit IgG) |
|
MBS524575-01mg |
MyBiosource |
0.1mg |
EUR 365 |
Anti-SARS-CoV-2 Spike RBD, Biotin (Polyclonal)(Rabbit IgG) |
|
MBS524575-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1400 |
SARS-CoV-2 Spike S1-NTD Antibody, Rabbit MAb |
|
MBS8123752-002mL |
MyBiosource |
0.02mL |
EUR 325 |
SARS-CoV-2 Spike S1-NTD Antibody, Rabbit MAb |
|
MBS8123752-01mL |
MyBiosource |
0.1mL |
EUR 580 |
SARS-CoV-2 Spike S1-NTD Antibody, Rabbit MAb |
|
MBS8123752-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2460 |
SARS-CoV-2 Spike Neutralizing Antibody, Rabbit MAb |
|
MBS8123644-002mg |
MyBiosource |
0.02mg |
EUR 325 |
SARS-CoV-2 Spike Neutralizing Antibody, Rabbit MAb |
|
MBS8123644-01mg |
MyBiosource |
0.1mg |
EUR 580 |
SARS-CoV-2 Spike Neutralizing Antibody, Rabbit MAb |
|
MBS8123644-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2460 |
SARS-CoV-2 Spike Neutralizing Antibody, Rabbit MAb |
|
MBS8123765-002mg |
MyBiosource |
0.02mg |
EUR 325 |
SARS-CoV-2 Spike Neutralizing Antibody, Rabbit MAb |
|
MBS8123765-01mg |
MyBiosource |
0.1mg |
EUR 580 |
SARS-CoV-2 Spike Neutralizing Antibody, Rabbit MAb |
|
MBS8123765-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2460 |
Anti-SARS-CoV-2 Spike RBD, Purified (Polyclonal)(Rabbit IgG) |
|
MBS524574-002mg |
MyBiosource |
0.02mg |
EUR 205 |
Anti-SARS-CoV-2 Spike RBD, Purified (Polyclonal)(Rabbit IgG) |
|
MBS524574-02mg |
MyBiosource |
0.2mg |
EUR 485 |
Anti-SARS-CoV-2 Spike RBD, Purified (Polyclonal)(Rabbit IgG) |
|
MBS524574-5x02mg |
MyBiosource |
5x0.2mg |
EUR 1945 |
Rabbit IgG Anti HCoV-229E Spike (S1) Polyclonal Antibody |
|
PAB21477-100 |
The Native Antigen Company |
0.1 |
EUR 409.44 |
|
Description: Polyclonal antibody against human coronavirus 229E. |
Rabbit IgG Anti HCoV-229E Spike (S1) Polyclonal Antibody |
|
PAB21477-500 |
The Native Antigen Company |
0.5 |
EUR 1270.82 |
|
Description: Polyclonal antibody against human coronavirus 229E. |
Rabbit IgG Anti HCoV-OC43 Spike (S1) Polyclonal Antibody |
|
PAB21478-100 |
The Native Antigen Company |
0.1 |
EUR 409.44 |
|
Description: Polyclonal antibody against human coronavirus OC43. |
Rabbit IgG Anti HCoV-OC43 Spike (S1) Polyclonal Antibody |
|
PAB21478-500 |
The Native Antigen Company |
0.5 |
EUR 1270.82 |
|
Description: Polyclonal antibody against human coronavirus OC43. |
Rabbit IgG Anti HCoV-NL63 Spike (S1) Polyclonal Antibody |
|
PAB21479-100 |
The Native Antigen Company |
0.1 |
EUR 409.44 |
|
Description: Polyclonal antibody against human coronavirus NL63. |
Rabbit IgG Anti HCoV-NL63 Spike (S1) Polyclonal Antibody |
|
PAB21479-500 |
The Native Antigen Company |
0.5 |
EUR 1270.82 |
|
Description: Polyclonal antibody against human coronavirus NL63. |
Rabbit IgG Anti HCoV-HKU1 Spike (S1) Polyclonal Antibody |
|
PAB21480-100 |
The Native Antigen Company |
0.1 |
EUR 409.44 |
|
Description: Polyclonal antibody against human coronavirus HKU1. |
Rabbit IgG Anti HCoV-HKU1 Spike (S1) Polyclonal Antibody |
|
PAB21480-500 |
The Native Antigen Company |
0.5 |
EUR 1270.82 |
|
Description: Polyclonal antibody against human coronavirus HKU1. |
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit MAb |
|
BSV-COV-AB-09 |
BioServUK |
50 ul |
EUR 344 |
|
Description: SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit MAb (Spike (S1), Monoclonal) |
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit MAb |
|
BSV-COV-AB-10 |
BioServUK |
100 ul |
EUR 569 |
|
Description: SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit MAb (Spike (S1), Monoclonal) |
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit mAb |
|
MBS669415-005mL |
MyBiosource |
0.05mL |
EUR 785 |
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit mAb |
|
MBS669415-01mL |
MyBiosource |
0.1mL |
EUR 1255 |
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit mAb |
|
MBS669415-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5635 |
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit MAb |
|
MBS9457574-005mL |
MyBiosource |
0.05mL |
EUR 530 |
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit MAb |
|
MBS9457574-01mL |
MyBiosource |
0.1mL |
EUR 825 |
SARS-CoV-2 (2019-nCoV) Spike Antibody, Rabbit MAb |
|
MBS9457574-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3560 |
SARS Spike Antibody |
|
24216 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24216-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
|
24217 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24217-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
|
24218 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24218-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
|
24219 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24219-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
|
24318 |
SAB |
100ul |
EUR 479 |
SARS Spike Antibody |
|
24318-100ul |
SAB |
100ul |
EUR 468 |
SARS Spike Antibody |
|
20-abx137184 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
SARS Spike Antibody |
|
20-abx137200 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
|
SARS Spike Antibody |
|
abx137749-100tests |
Abbexa |
100 tests |
EUR 362.5 |
SARS Spike Antibody |
|
MBS151089-01mg |
MyBiosource |
0.1mg |
EUR 445 |
SARS Spike Antibody |
|
MBS151089-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1965 |
SARS Spike Antibody |
|
MBS151173-01mg |
MyBiosource |
0.1mg |
EUR 445 |
SARS Spike Antibody |
|
MBS151173-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1965 |
SARS Spike Antibody |
|
MBS150443-01mg |
MyBiosource |
0.1mg |
EUR 445 |
SARS Spike Antibody |
|
MBS150443-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1965 |
SARS Spike Antibody |
|
MBS150542-01mg |
MyBiosource |
0.1mg |
EUR 445 |
SARS Spike Antibody |
|
MBS150542-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1965 |
SARS Spike Antibody |
|
MBS9403751-01mL |
MyBiosource |
0.1mL |
EUR 495 |
SARS Spike Antibody |
|
MBS9403751-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2075 |
SARS Spike Antibody |
|
MBS9404782-01mL |
MyBiosource |
0.1mL |
EUR 495 |
SARS Spike Antibody |
|
MBS9404782-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2075 |
SARS Spike Antibody |
|
MBS9407060-01mL |
MyBiosource |
0.1mL |
EUR 495 |
SARS Spike Antibody |
|
MBS9407060-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2075 |
SARS Spike Antibody |
|
MBS9413028-01mL |
MyBiosource |
0.1mL |
EUR 495 |
SARS Spike Antibody |
|
MBS9413028-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2075 |
SARS Spike Antibody |
|
MBS9413483-01mL |
MyBiosource |
0.1mL |
EUR 495 |
SARS Spike Antibody |
|
MBS9413483-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2075 |
SARS-CoV Spike S1 Rabbit pAb |
|
E45R29002N |
EnoGene |
50 ul |
EUR 297.75 |
SARS-CoV Spike S1 Rabbit pAb |
|
MBS9143748-002mL |
MyBiosource |
0.02mL |
EUR 200 |
SARS-CoV Spike S1 Rabbit pAb |
|
MBS9143748-005mL |
MyBiosource |
0.05mL |
EUR 255 |
SARS-CoV Spike S1 Rabbit pAb |
|
MBS9143748-01mL |
MyBiosource |
0.1mL |
EUR 345 |
SARS-CoV Spike S1 Rabbit pAb |
|
MBS9143748-02mL |
MyBiosource |
0.2mL |
EUR 545 |
The furthest distance from affected person with PCR-positive air samples was 5.5 m. The airborne SARS-CoV-2 detection was comparable between the 2 sorts of wards with 60%-87.5% success charge. Excessive prevalence of the virus was present in bathroom areas, each on surfaces and in air. Lastly, no profitable tradition try was recorded from the environmental air or floor samples.